Tian Y, Ma R, Zhao W, Wang S, Zhou C, Wu W
Nat Commun. 2025; 16(1):1976.
PMID: 40000630
PMC: 11861273.
DOI: 10.1038/s41467-025-57309-4.
Wang Y, Armendariz D, Wang L, Zhao H, Xie S, Hon G
Genome Biol. 2025; 26(1):10.
PMID: 39825430
PMC: 11740497.
DOI: 10.1186/s13059-025-03474-0.
Suha H, Tasnim S, Rahman S, Alodhayb A, Albrithen H, Poirier R
ACS Omega. 2024; 9(50):49639-49661.
PMID: 39713673
PMC: 11656217.
DOI: 10.1021/acsomega.4c07808.
Waliany S, Nagasaka M, Park L, Lam C, Jiang Z, Lin F
Cancer Med. 2024; 13(24):e70272.
PMID: 39692700
PMC: 11653943.
DOI: 10.1002/cam4.70272.
Cen S, Yuan M, Sun Q, Hou G, Ying J, Xu Q
Sci Rep. 2024; 14(1):25030.
PMID: 39443515
PMC: 11500361.
DOI: 10.1038/s41598-024-76296-y.
Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a Single-Institution Prospective Cohort.
Verma S, Chapman A, Pickard L, Porplycia D, McConkey H, Jarosz P
Explor Target Antitumor Ther. 2024; 5(5):1100-1109.
PMID: 39351438
PMC: 11438559.
DOI: 10.37349/etat.2024.00265.
HER3 receptor and its role in the therapeutic management of metastatic breast cancer.
Zhu M, Yu M, Meng Y, Yang J, Wang X, Li L
J Transl Med. 2024; 22(1):665.
PMID: 39020378
PMC: 11253420.
DOI: 10.1186/s12967-024-05445-8.
Construction of a prognostic model for autophagy in Wilm's tumor.
Shi H, Zhang M, Zhang Y
Pediatr Surg Int. 2024; 40(1):122.
PMID: 38704513
DOI: 10.1007/s00383-024-05712-1.
The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer.
ONeill C, Sun K, Sundararaman S, Chang J, Glynn S
Front Physiol. 2024; 15:1358850.
PMID: 38601214
PMC: 11004480.
DOI: 10.3389/fphys.2024.1358850.
HER2-Positive Early Breast Cancer: Time for Ultimate De-Escalation?.
Tauber N, Cirkel C, Claussen A, Fick F, Kontomanolis E, Krawczyk N
Cancers (Basel). 2024; 16(6).
PMID: 38539456
PMC: 10968736.
DOI: 10.3390/cancers16061121.
Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.
Meng P, Dalal H, Chen Y, Brueffer C, Gladchuk S, Alcaide M
NPJ Breast Cancer. 2024; 10(1):14.
PMID: 38374091
PMC: 10876644.
DOI: 10.1038/s41523-024-00621-x.
Systemic Therapies for HER2-Positive Advanced Breast Cancer.
Angelis V, Okines A
Cancers (Basel). 2024; 16(1).
PMID: 38201451
PMC: 10777942.
DOI: 10.3390/cancers16010023.
PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer.
McGale J, Khurana S, Huang A, Roa T, Yeh R, Shirini D
J Clin Med. 2023; 12(15).
PMID: 37568284
PMC: 10419459.
DOI: 10.3390/jcm12154882.
Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies.
Shayeb A, Kurzrock R, Adashek J, Kato S
JCO Precis Oncol. 2023; 7:e2200604.
PMID: 37437231
PMC: 10581650.
DOI: 10.1200/PO.22.00604.
Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies.
Loh H, Bin Mahfut F, Chen S, Huang Y, Huo J, Zhang W
MAbs. 2023; 15(1):2231129.
PMID: 37403264
PMC: 10324450.
DOI: 10.1080/19420862.2023.2231129.
The quest for balance between capturing data and model complexity: A quantitative clinical pharmacology approach applied to monoclonal antibodies.
Pressly M, Peletier L, Zheng S, Sharma V, Lien Y, Wang W
CPT Pharmacometrics Syst Pharmacol. 2023; 12(5):639-655.
PMID: 36752286
PMC: 10196441.
DOI: 10.1002/psp4.12927.
Expanding the reach of HER2-targeted therapies: transformation of an historical paradigm.
Cobain E, Hayes D
J Clin Invest. 2022; 132(24).
PMID: 36519541
PMC: 9753983.
DOI: 10.1172/JCI166384.
Targeting HER2-positive breast cancer: advances and future directions.
Swain S, Shastry M, Hamilton E
Nat Rev Drug Discov. 2022; 22(2):101-126.
PMID: 36344672
PMC: 9640784.
DOI: 10.1038/s41573-022-00579-0.
Molecular and clinicopathological characteristics of gene fusions in 32,131 Chinese patients with solid tumors.
Guan Y, Wang Y, Li H, Meng J, You X, Zhu X
Front Oncol. 2022; 12:986674.
PMID: 36276102
PMC: 9582139.
DOI: 10.3389/fonc.2022.986674.
Editorial: Translating clinical genomics and health informatics into precision oncology.
Yang H, Crawford D, Abazeed M
Front Genet. 2022; 13:1029212.
PMID: 36263433
PMC: 9574329.
DOI: 10.3389/fgene.2022.1029212.